Apr 18, 2013
GlobeImmune to Present at 12th Annual Needham Healthcare Conference
LOUISVILLE, Colo., April 18, 2013 - GlobeImmune, Inc., today announced that Timothy C. Rodell, M.D., president and chief executive officer of GlobeImmune, will present at the 12th Annual Needham Healthcare Conference at 2:20 p.m. EDT on Tuesday, April 30, at The Westin New York Grand Central Hotel in New York.
Report Published: "GlobeImmune, Inc. - Mergers & Acquisitions (M&A),...
Company Mergers & Acquisitions , Partnerships & Alliances and Investments reports offer a comprehensive breakdown of the organic and inorganic growth activity undertaken by an organization to sustain its competitive advantage.
GlobeImmune Initiates Phase 1a Clinical Trial of GI-13020 in Healthy Volunteers
LOUISVILLE, Colo., Jan. 28, 2013 - GlobeImmune, Inc. , today announced the initiation of a Phase 1a clinical trial to investigate the safety and immunogenicity of GI-13020 in healthy volunteers.The GI-13020 Tarmogen , which GlobeImmune is developing in collaboration with Gilead Sciences, Inc., consists of whole, heat-killed, recombinant S.
GI-13020 TarmogenA for the Treatment of Chronic Hepatitis B Generates Antigen-specific T Cell Responses in Key Preclinical Studies
GlobeImmune, Inc. today announced that GI-13020, an investigational therapeutic vaccine designed using the company's proprietary TarmogenA product platform for the treatment of chronic hepatitis B virus infection, demonstrated immunogenicity in two preclinical studies.
GI-5005 Improves Virologic Clearance of HCV in Combination with PegIFN/Ribavirin in IL28B T/T Patients
GlobeImmune, Inc., today announced Phase 2b clinical data showing that GI-5005, a Tarmogen product candidate for the treatment of chronic hepatitis C virus infection, improved virologic clearance of HCV in combination with pegylated-interferon plus ribavirin in genotype 1, IL28B T/T patients.